Advertisement
Erratum Free access | 10.1172/JCI66861
Find articles by Kyme, P. in: JCI | PubMed | Google Scholar
Find articles by Thoennissen, N. in: JCI | PubMed | Google Scholar
Find articles by Tseng, C. in: JCI | PubMed | Google Scholar
Find articles by Thoennissen, G. in: JCI | PubMed | Google Scholar
Find articles by Wolf, A. in: JCI | PubMed | Google Scholar
Find articles by Shimada, K. in: JCI | PubMed | Google Scholar
Find articles by Krug, U. in: JCI | PubMed | Google Scholar
Find articles by Lee, K. in: JCI | PubMed | Google Scholar
Find articles by Müller-Tidow, C. in: JCI | PubMed | Google Scholar
Find articles by Berdel, W. in: JCI | PubMed | Google Scholar
Find articles by Hardy, W. in: JCI | PubMed | Google Scholar
Find articles by Gombart, A. in: JCI | PubMed | Google Scholar
Find articles by Koeffler, H. in: JCI | PubMed | Google Scholar
Find articles by Liu, G. in: JCI | PubMed | Google Scholar
Published November 1, 2012 - More info
The myeloid-specific transcription factor, CCAAT/enhancer-binding protein ε (C/EBPε) is a critical mediator of myelopoiesis. Mutation of this gene is responsible for neutrophil-specific granule deficiency in humans, a condition that confers susceptibility to Staphylococcus aureus infection. We found that C/EBPε-deficient mice are severely affected by infection with S. aureus, and C/EBPε deficiency in neutrophils contributes to the infectious phenotype. Conversely, exposure to the epigenetic modulator nicotinamide (vitamin B3) increased expression of C/EBPε in WT myeloid cells. Further, nicotinamide increased the activity of C/EBPε and select downstream antimicrobial targets, particularly in neutrophils. In a systemic murine infection model as well as in murine and human peripheral blood, nicotinamide enhanced killing of S. aureus by up to 1,000 fold but had no effect when administered to either C/EBPε-deficient mice or mice depleted of neutrophils. Nicotinamide was efficacious in both prophylactic and therapeutic settings. Our findings suggest that C/EBPε is an important target to boost killing of bacteria by the innate immune system.
Pierre Kyme, Nils H. Thoennissen, Ching Wen Tseng, Gabriela B. Thoennissen, Andrea J. Wolf, Kenichi Shimada, Utz O. Krug, Kunik Lee, Carsten Müller-Tidow, Wolfgang E. Berdel, W. David Hardy, Adrian F. Gombart, H. Phillip Koeffler, George Y. Liu
Original citation: J. Clin. Invest. 2012;122(9):3316–3329. doi:10.1172/JCI62070.
Citation for this erratum: J. Clin. Invest. 2012;122(11):4301. doi:10.1172/JCI66861.
The e-mail address given for Pierre Kyme as corresponding author was incorrect. The correct address is below.
E-mail: pierre.kyme@gmail.com (P. Kyme).
The JCI regrets the error.